Search
Lilly Invests in AI-Powered Pharma Startup Superluminal
3 week ago /
Read about 0 minute
Author：小编
On August 14, local time, Eli Lilly and Company announced a significant $1.3 billion partnership with Superluminal, a Boston-based AI pharmaceutical startup. This strategic alliance aims to expedite the development of AI-driven medications, with a particular focus on small molecule drugs aimed at treating obesity and other cardiometabolic disorders. Superluminal, which has garnered investments from various capital firms including NVIDIA, brings its advanced AI-powered drug discovery platform to the table. Through this collaboration, Lilly will harness Superluminal's technology to intensify its efforts in developing drugs targeting G-protein-coupled receptors (GPCRs).
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
